Simulations Plus hosts the 2022 Model-Informed Drug Development (MIDD+) scientific conference

0

Participants from 57 countries spent two days advancing model-based drug development

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc., (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, announced record attendance and delivery of virtual content for the MIDD+ 2022 scientific conference held February 16-17, 2022. The conference focused on presenting real case studies using modeling and simulations. The tracks included dedicated sessions covering all stages of the drug development process, including discovery, preclinical, clinical, and post-approval/generics.

Shawn O’Connor, President and CEO of Simulations Plus, said, “We are thrilled with the momentum that followed our inaugural MIDD+ event last year, resulting in record attendance at this year’s MIDD+ Science Conference. year. As a leader in providing software tools and services to support industry and our customers in their efforts to leverage modeling and simulation for more efficient and faster drug development, we were delighted to provide this virtual forum.

The conference opened Feb. 16, with Rajanikanth Madabushi, Ph.D., associate director for science guidance and policy, Office of Clinical Pharmacology, OTS/CDER at the U.S. Food and Drug Administration (FDA). United, who delivered her keynote address titled “Advancing Model-Based Drug Development (MIDD): A Holistic and Integrative Approach.” On day two, speakers from around the world, including representatives from the U.S. FDA , Brazilian regulatory agency ANVISA, Health Canada and MHRA-UK, provided attendees with case studies and global regulatory perspectives on MIDD development and validation.

Other session topics ranged from building and validating machine learning models to using population PK/PD approaches to support late-phase dose selection. Of note, the Women in Science Roundtable, led by Cognigen Division President Jill Fiedler-Kelly, shed light on meaningful topics for women in the science-based pharma industry, including the power of mentorship. , closing the STEM gap and bringing your “authentic self” to the workplace. All presentations can be re-streamed in the Simulations Plus Resource Center. Presentations and slideshows are available on our website and YouTube channel.

Programming and speaker requests for next year’s MIDD+ 2023 science conference are invited and can be sent to Arlene Padron at [email protected]

About Simulation Plus

Serving customers worldwide for 25 years, Simulations Plus is a leading provider in the biosimulation market, providing software and consulting services supporting drug discovery, development, research and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and enforced by leading pharmaceutical, biotechnology and regulatory agencies around the world. For more information, visit our website at www.simulations-plus.com. follow us on Twitter | LinkedIn.

Environment, Social and Governance (ESG)

We focus our environmental, social and governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG report.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 – Except for historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe”, “expect” and “anticipate” mean that these are our best estimates at the time of writing, but there can be no guarantee that the results or expected or anticipated events will actually occur, so our actual future results could differ materially from these statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and enhanced versions of our existing software by our customers, the general economic of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical personnel, our ability to identify and complete acquisitions on favorable terms for the Company and a sustainable market. Further information about our risk factors is contained in our quarterly and annual reports and filed with the United States Securities and Exchange Commission.

Share.

Comments are closed.